Celcuity Inc. (CELC) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $124.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 27%; Elevated put/call ratio: 5.09; Below-average business quality.
Celcuity is a clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor, for HR+/HER2- advanced breast cancer in Phase 3 trials (VIKTORIA-1 and VIKTORIA-2) and metastatic castration-resistant prostate cancer. The company has no revenue; commercialization depends... Read more
Sell if holding. Engine safety override at $124.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 27%; Elevated put/call ratio: 5.09; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.4/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductgedatolisib10-K Item 1A: 'Our future success and ability to generate revenue, if ever, is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize gedatolisib'
Material Events(8-K, last 90d)
- 2026-02-12Item 5.02LOWCharles (Chip) R. Romp appointed as director, filling a vacancy created by board expansion from 7 to 8 members, effective February 11, 2026. Serves through 2026 Annual Meeting. No committees assigned yet.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $124.03: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 27%; Elevated put/call ratio: 5.09; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $116.23. Score 4.4/10, moderate confidence.
Take-profit target: $126.51 (+1.2% upside). Prior stop was $116.23. Stop-loss: $116.23.
Concentration risk — Product: gedatolisib; Target reached (-9.1% upside); Quality below floor (1.5 < 4.0).
Celcuity Inc. trades at a P/E of N/A (forward -110.3). TrendMatrix value score: 4.0/10. Verdict: Sell.
17 analysts cover CELC with a consensus score of 4.3/5. Average price target: $131.
What does Celcuity Inc. do?Celcuity is a clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor, for HR+/HER2- advanced breast...
Celcuity is a clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor, for HR+/HER2- advanced breast cancer in Phase 3 trials (VIKTORIA-1 and VIKTORIA-2) and metastatic castration-resistant prostate cancer. The company has no revenue; commercialization depends entirely on regulatory approval of gedatolisib.